ABSTRACT
OBJECTIVE Estimate the prevalence of mild cognitive impairment (MCI) and probable dementia in the racially and ethnically diverse community-based Northern Manhattan Study cohort and examine sociodemographic, vascular risk factor, and brain imaging correlates.
METHODS Cases of MCI and probable dementia were adjudicated by a team of neuropsychologists and neurologists and prevalence was estimated across race/ethnic groups. Ordinal proportional odds models were used to estimate race/ethnic differences in prevalence rates for MCI or probable dementia adjusting for sociodemographic variables (model 1), model 1 plus potentially modifiable vascular risk factors (model 2), and model 1 plus structural imaging markers of brain integrity (model 3).
RESULTS There were 989 participants with cognitive outcome determinations (mean age 69 ± 9 years; 68% Hispanic, 16% Black, 14% White; 62% women; mean (±SD) follow-up five (±0.6) years). Prevalence rates for MCI (20%) and probable dementia (5%) were significantly different by race/ethnicity even after accounting for age and education difference across race-ethnic groups; Hispanic and Black participants had greater prevalence rates than Whites. Adjusting for sociodemographic and brain imaging factors explained the most variance in the race/ethnicity associations. White matter hyperintensity burden explained much of the disparity between Black and White, but not between Hispanic and White, participants.
CONCLUSIONS In this diverse community-based cohort, white matter hyperintensity burden partially explained disparities in MCI and dementia prevalence in Black but not Hispanic participants compared to Whites. Longer follow-up and incidence data are needed to further clarify these relationships.
Competing Interest Statement
Clinton Wright reports royalties from chapters on vascular dementia in UpToDate.com. Yaakov Stern consults for Eisai, Lilly, and Arcadia. Mitchell Elkind reports royalties from chapters on stroke in UpToDate.com.
Funding Statement
Janet DeRosa, Michelle Moon, Ying Kuen Cheung, Xiaoyan Sun, Bonnie Levin, Yaakov Stern, Tatjana Rundek, Mitchell Elkind, and Ralph Sacco are supported by NINDS grant NS29993 to the University of Miami and (via subcontract) to Columbia University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is approved by the IRBs of Columbia University Medical Center and the University of Miami School of Medicine.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data for this analysis are available upon reasonable request.
